Lisinopril Dihydrate: Potent Long-Acting ACE Inhibitor for Hypertension and Cardiovascular Research

Executive Summary: Lisinopril dihydrate is a long-acting ACE inhibitor with an IC₅₀ of 4.7 nM, enabling precise inhibition of the renin-angiotensin system in translational models (Tieku & Hooper 1992). It is the dihydrate salt of a lysine analogue of MK 421, formulated for high water solubility and stability (APExBIO). Lisinopril dihydrate reduces angiotensin II and aldosterone levels, increases plasma renin, and lowers blood pressure by vasodilation. The product exhibits 98% purity and is validated by mass spectrometry and NMR, supporting reproducible research outputs. Distinct from other ACE inhibitors, it does not inhibit aminopeptidases N, A, or W at relevant concentrations, ensuring selectivity (Tieku & Hooper 1992).

Biological Rationale

The renin-angiotensin system (RAS) is central to blood pressure regulation and fluid homeostasis. Angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. Inhibition of ACE suppresses formation of angiotensin II, reducing vasoconstriction, sodium retention, and aldosterone secretion (Tieku & Hooper 1992). Lisinopril dihydrate, as a selective and long-acting ACE inhibitor, enables controlled RAS modulation in research on hypertension, heart failure, myocardial infarction, and diabetic nephropathy. Its lysine-based structure, derived from MK 421, confers both oral activity and high target selectivity. Unlike sulfhydryl ACE inhibitors, lisinopril dihydrate does not inhibit cell-surface zinc aminopeptidases N, A, or W, minimizing off-target effects.

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate binds reversibly to ACE, blocking the active site responsible for cleaving angiotensin I to angiotensin II (Tieku & Hooper 1992). The inhibition constant (IC₅₀) of 4.7 nM indicates high potency under physiological buffer conditions (pH 7.4, 37°C). This action prevents the subsequent increase in systemic vascular resistance and aldosterone-mediated sodium retention. Lisinopril is not metabolized by the liver and is excreted unchanged in urine, allowing for consistent pharmacokinetics in experimental models (APExBIO). The dihydrate formulation enhances aqueous solubility to ≥2.46 mg/mL with gentle warming. It does not inhibit other peptidases involved in peptide metabolism, such as aminopeptidases N (CD13), A, or W, as demonstrated by direct activity assays (Tieku & Hooper 1992).

Evidence & Benchmarks

• Lisinopril dihydrate exhibits an IC₅₀ of 4.7 nM for ACE inhibition in vitro, enabling reliable RAS pathway suppression (Tieku & Hooper 1992).
• It does not significantly inhibit aminopeptidase N (AP-N), aminopeptidase A (AP-A), or aminopeptidase W (AP-W) at concentrations up to 10 µM, confirming pathway specificity (Tieku & Hooper 1992).
• Decreases in plasma angiotensin II and aldosterone concentrations, and corresponding increases in plasma renin, have been consistently observed in animal models following lisinopril administration (APExBIO).
• Validated using mass spectrometry and NMR, the product's purity is ≥98%, ensuring experimental reproducibility (APExBIO).
• Lisinopril dihydrate is insoluble in ethanol but readily soluble in water at ≥2.46 mg/mL with gentle warming and ultrasonic treatment, supporting a range of dosing and assay conditions (APExBIO).

Applications, Limits & Misconceptions

Lisinopril dihydrate is a reference standard for pharmacological studies of hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy. It is a preferred tool for dissecting the renin-angiotensin system and evaluating the impact of ACE inhibition on blood pressure and end-organ protection. For advanced workflows, see Lisinopril Dihydrate: Applied ACE Inhibitor Workflows, which details experimental and troubleshooting protocols. This article extends previous coverage by emphasizing benchmark selectivity and biophysical properties.

For strategic application and competitive context, the article Lisinopril Dihydrate: Strategic ACE Inhibition for Next-G provides a framework for mechanistic studies; this dossier further clarifies selectivity and compound handling. Recent advances in peptidase selectivity and translational modeling are discussed in Lisinopril Dihydrate: Unveiling New Mechanistic Insights, while our article updates the field with product-specific purity, solubility, and validation data.

Common Pitfalls or Misconceptions

• Not a broad-spectrum peptidase inhibitor: Lisinopril dihydrate does not inhibit aminopeptidase N, A, or W, and is selective for ACE only (Tieku & Hooper 1992).
• Not suitable for ethanol-based formulations: The compound is insoluble in ethanol and should be dissolved in water with gentle warming and ultrasonic treatment (APExBIO).
• Not designed for long-term solution storage: Lisinopril dihydrate solutions degrade over time; prepare fresh solutions for each experiment and store the solid desiccated at room temperature (APExBIO).
• Not an irreversible inhibitor: Lisinopril dihydrate binds ACE reversibly, which can influence experimental design and washout studies (Tieku & Hooper 1992).
• Not appropriate for in vivo studies without pharmacokinetic validation: While lisinopril is orally bioavailable in clinical use, dosing regimens and PK must be established for specific animal models and research endpoints.

Workflow Integration & Parameters

Lisinopril dihydrate (SKU: B3290) from APExBIO is supplied as a solid with a molecular weight of 441.52 g/mol and formula C₂₁H₃₅N₃O₇. Reconstitute at concentrations ≥2.46 mg/mL in water, applying gentle warming (≤37°C) and ultrasonic agitation as needed. Do not use ethanol as a solvent. Store desiccated at room temperature; avoid repeated freeze-thaw cycles and long-term storage of solutions.

For cardiovascular and renal disease modeling, standard dosing ranges from 0.1 to 10 mg/kg in rodent models, with dosing intervals adjusted based on pharmacokinetic data and study design (APExBIO). Shipping is on blue ice for small molecule protection. For broader experimental strategies and troubleshooting, see Lisinopril Dihydrate: Precision ACE Inhibitor for Hypertension Models; this article extends those insights with up-to-date purity and selectivity data.

Conclusion & Outlook

Lisinopril dihydrate is a validated, highly selective, and potent ACE inhibitor, enabling reproducible research on the renin-angiotensin system, hypertension, and cardiovascular disease. Its benchmark selectivity for ACE, high purity, and robust solubility profile make it the preferred choice for mechanistic and translational studies. For detailed product specifications and ordering information, refer to the Lisinopril dihydrate product page by APExBIO. Ongoing research may further define its utility in emerging disease models and combination therapies.